3-甲基-4-硝基吡啶 | 1678-53-1

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 中文名称: 3-甲基-4-硝基吡啶
• 中文别名: 4-硝基-3-甲基吡啶；4-硝基-3-甲基吡啶盐酸盐
• 英文名称: 3-methyl-4-nitropyridine
• 英文别名: 3-Methyl-4-nitro-pyridin；4-Nitro-3-picolin；4-nitro-3-methylpyridine；4-Nitro-3-methyl-pyridin
• CAS: 1678-53-1
• 化学式: C₆H₆N₂O₂
• mdl: MFCD03095084
• 分子量: 138.126
• InChiKey: UYAWSMUOLFSNGC-UHFFFAOYSA-N

物化性质

• 熔点：
  28-29 °C(Solv: ligroine (8032-32-4))
• 沸点：
  67-69 °C(Press: 1.5 Torr)
• 密度：
  1.246±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  58.7
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xn
• RTECS号：
  XF9900000
• 海关编码：
  2933399090
• 危险类别：
  4.1
• 安全说明：
  S13,S25,S46
• 危险类别码：
  R22,R10
• 包装等级：
  III
• 危险品运输编号：
  1332
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

SDS

Name:	4-Nitro-3-picoline Material Safety Data Sheet
Synonym:	3-Methyl-4-nitropyridin
CAS:	1678-53-1

Section 1 - Chemical Product MSDS Name:4-Nitro-3-picoline Material Safety Data Sheet
Synonym:3-Methyl-4-nitropyridin

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
1678-53-1	4-Nitro-3-picoline		unlisted

Hazard Symbols: XN
Risk Phrases: 21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful in contact with skin and if swallowed. Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 1678-53-1: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: cream
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H6N2O2
Molecular Weight: 138.12

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, acids, acid chlorides, acid anhydrides.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Will not occur.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 1678-53-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Nitro-3-picoline - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 21/22 Harmful in contact with skin and if
swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 1678-53-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 1678-53-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 1678-53-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-甲基-4-硝基吡啶 在 palladium on activated charcoal sodium hydroxide 、 氢气 、 四丁基硫酸氢铵 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 20.0~90.0 ℃ 、2.94 kPa 条件下， 反应 6.0h， 生成 1-苯磺酰基-5-氮杂吲哚
  参考文献：
  名称：

  合成玫瑰果碱工业。I：精制新的6 H-吡啶并[4,3：b]咔唑等类似物：A。Synthèse等人。

  摘要：

  修饰的玫瑰树碱的全合成，并描述了由11到13步分别由2-氯烟酸和5-甲氧基吲哚和5-氮杂吲哚组成，总收率为11％和18％。还开发了一条通往5-氮杂吲哚的新途径。合成策略要求经常使用均芳族和杂芳族金属化反应，因此必须解决与吡啶环的存在有关的问题。关于文献中描述的大量合成，这种方法的独创性首先在于在碱性介质中形成环C。在图1中，这种条件是由吡啶A环的存在决定的。。两种合成方法均已推断出可产生数公斤的最终产物。第一部分涉及前体的制备。

  DOI：

  10.1016/s0040-4020(01)80387-2
• 作为产物：
  描述：

  3-甲基-4-硝基吡啶-N-氧化物 在 三氯化磷 作用下， 反应 3.5h， 以81%的产率得到3-甲基-4-硝基吡啶
  参考文献：
  名称：

  合成玫瑰果碱工业。I：精制新的6 H-吡啶并[4,3：b]咔唑等类似物：A。Synthèse等人。

  摘要：

  修饰的玫瑰树碱的全合成，并描述了由11到13步分别由2-氯烟酸和5-甲氧基吲哚和5-氮杂吲哚组成，总收率为11％和18％。还开发了一条通往5-氮杂吲哚的新途径。合成策略要求经常使用均芳族和杂芳族金属化反应，因此必须解决与吡啶环的存在有关的问题。关于文献中描述的大量合成，这种方法的独创性首先在于在碱性介质中形成环C。在图1中，这种条件是由吡啶A环的存在决定的。。两种合成方法均已推断出可产生数公斤的最终产物。第一部分涉及前体的制备。

  DOI：

  10.1016/s0040-4020(01)80387-2

文献信息

• Metal-free methylation of a pyridine N-oxide C–H bond by using peroxides
  作者：Gang Li、Suling Yang、Bingjie Lv、Qingqing Han、Xingxing Ma、Kai Sun、Zhiyong Wang、Feng Zhao、Yunhe Lv、Hankui Wu

  DOI：10.1039/c5ob01900a

  日期：——

  Metal-free methylation of a pyridine N-oxide C–H bond was developed using peroxide as a methyl reagent under neat conditions. Pyridine N-oxide derivatives with various groups (e.g., Cl, NO₂, and OCH₃) were all suitable substrates.

  使用过氧化物作为甲基试剂，在无溶剂条件下开发了对吡啶N-氧化物C-H键的无金属甲基化方法。具有各种基团（如Cl、NO2和OCH3）的吡啶N-氧化物衍生物均是合适的底物。
• Metal-Free, Phosphonium Salt-Mediated Sulfoximination of Azine <i>N</i>-Oxides: Approach for the Synthesis of <i>N</i>-Azine Sulfoximines
  作者：Sravan Kumar Aithagani、Mukesh Kumar、Mahipal Yadav、Ram A. Vishwakarma、Parvinder Pal Singh

  DOI：10.1021/acs.joc.6b00593

  日期：2016.7.15

  method for the synthesis of N-azine sulfoximines by the nucleophilic substitution of azine N-oxides with NH-sulfoximines. The present method works at room temperature with wide functional group compatibility and gives several unprecedented N-azine sulfoximines. The reaction conditions were also found suitable with enantiopure substrates and furnished products without any racemization. It also finds

  在本文中，我们报道了一种简单且无金属的方法，该方法通过用NH-亚砜肟酮亲核取代N-嗪氮氧化物来合成N-嗪亚砜肟。本方法在室温下具有宽泛的官能团相容性，并提供了几种前所未有的N-嗪亚磺酰亚胺。还发现反应条件适用于对映纯底物和提供的产物，没有任何消旋作用。还发现了其在基于嗪的功能分子如2,2'-联吡啶，1,10-菲咯啉和奎宁的磺化中的应用。
• [EN] ANNELATED PYRROLES AND THEIR USE AS CRAC INHIBITORS<br/>[FR] PYRROLES CONDENSÉS ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE CRAC
  申请人：GRUENENTHAL GMBH

  公开号：WO2015022073A1

  公开（公告）日：2015-02-19

  The invention relates to substituted bicyclic pyrroloheterocyclyl compounds of general formula (I), wherein A1 and A2 represent direct bond or C(=O), with the proviso that 0 or 1 of A1 and A2 represents C(=O); m and n independently denote 0, 1, 2 or 3, with the proviso that the sum [n + m] is 1, 2, 3 or 4; R1 denotes H, F, CI, Br, I, CN, CF3, CF2H, CFH2, CO2H, CO2R13, R13, OH. O-R13, NH2, N(H)R13, N(R13)2, R2 represents 0 to 4 substituents, each independently selected from F, CI, Br, CN. CF3, CF2H, CFH2, R13, OH, O-R13, NH2, N(H)R13 and N(R13)2; Ar1 represents phenyl or 5- or 6-membered heteroaryl, in each case unsubstituted or substituted with one, two, three or four substituents, independently selected from F, CI, Br, CN, CF3. CF2H, CFH2, R13 and O- R13; or C3-6-cycloalkyl or 3 to 7 membered heterocycloalkyl, in each case unsubstituted or mono- or polysubstituted; Ar2 represents phenyl or 5- or 6-membered heteroaryl, wherein said phenyl or said heteroaryl may be unsubstituted or mono- or polysubstituted and may be condensed with a 4-, 5-, 6-or 7- membered ring, being carbocyclic or heterocyclic, wherein said condensed ring may be saturated, partially unsaturated or aromatic and may be unsubstituted or mono- or polysubstituted; useful as ICRAC inhibitors, to pharmaceutical compositions containing these compounds and to these compounds for the use in the treatment and/or prophylaxis of diseases and/or disorders, in particular inflammatory diseases and/or inflammatory disorders.

  该发明涉及通式(I)的取代双环吡咯杂环基化合物，其中A1和A2代表直接键或C(=O)，但A1和A2中的0或1个代表C(=O)；m和n独立地表示0、1、2或3，但要求总和[n + m]为1、2、3或4；R1代表H、F、CI、Br、I、CN、CF3、CF2H、CFH2、CO2H、CO2R13、R13、OH、O-R13、NH2、N(H)R13、N(R13)2；R2表示0到4个取代基，每个独立地选自F、CI、Br、CN、CF3、CF2H、CFH2、R13、OH、O-R13、NH2、N(H)R13和N(R13)2；Ar1表示苯基或5-或6-成员杂芳基，每种情况下未取代或取代为一个、两个、三个或四个取代基，独立地选自F、CI、Br、CN、CF3、CF2H、CFH2、R13和O-R13；或C3-6-环烷基或3到7-成员杂环烷基，每种情况下未取代或单取代或多取代；Ar2表示苯基或5-或6-成员杂芳基，其中所述苯基或所述杂芳基可以未取代或单取代或多取代，并且可以与4-、5-、6-或7-成员环融合，为碳环或杂环，所述融合环可以饱和、部分不饱和或芳香，并且可以未取代或单取代或多取代；用作ICRAC抑制剂，用于含有这些化合物的药物组合物，以及用于治疗和/或预防疾病和/或疾病，特别是炎症性疾病和/或炎症性疾病的这些化合物。
• A concise synthesis of functionalized 2,3-dihydrofuro[3,2-b], [3,2-c], and [2,3-b]pyridines
  作者：Jeffrey T. Kuethe

  DOI：10.1016/j.tet.2019.07.004

  日期：2019.8

  A strategy for the efficient and rapid one-pot synthesis of 2-aryl-2,3-dihydrofuro[3,2-b], [3,2-c], and [2,3-b]pyridines from readily available o-nitropicolines and aromatic aldehydes is described. The key transformation involves reaction of o-nitropicolines with aromatic aldehydes in the presence of TBAF and Hünig's base giving rise to functionalized products having molecular complexity suitable for

  从容易获得的邻域高效，快速一锅合成2-芳基-2,3-二氢呋喃[3,2- b ]，[3,2- c ]和[2,3- b ]吡啶的策略描述了硝基苯胺和芳香醛。关键的转化包括在TBAF和Hünig碱的存在下邻硝基苯胺与芳族醛的反应，从而产生具有分子复杂性的官能化产物，适合进一步操作。
• [EN] TETRAHYDROQUINOLONES AND AZA-ANALOGUES THEREOF FOR USE AS DPP-IV INHIBITORS IN THE TREATEMENT OF DIABETES<br/>[FR] TETRAHYDROQUINOLONES ET AZA-ANALOGUES ASSOCIES UTILISES EN TANT QU'INHIBITEURS DE LA DPP-IV DANS LE TRAITEMENT DU DIABETE
  申请人：ASTRAZENECA AB

  公开号：WO2005123685A1

  公开（公告）日：2005-12-29

  Compound of formula (I) or a pharmaceutically-acceptable salt thereof, formula (I) wherein Ar is optionally substituted phenyl; R1 is selected from: formula a) or b) (wherein is a single or double bond); R5, R6, R7 and R8 are for example hydrogen or alkyl; R4 is selected from hydrogen, (3-4C)cycloalkyl and optionally substituted (1-4C)alkyl; R10 is for example selected from hydrogen, (1-4C)alkyl, (3-6C)cycloalkyl(1-4C)alkyl, hydroxy(1-4C)alkyl, (1-4C)alkoxy, aryl(1-4C)alkyl; Y is carbon and Ring A is optionally substituted phenylene; or each Y may independently be carbon or nitrogen and Ring A is optionally substituted 5- or 6-membered, heteroarylene ring; R11 is selected from hydrogen and optionally substituted phenyl; p is independently at each occurrence 0, 1 or 2; are described. Processes for making such compounds and their use as DPP-IV inhibitors in the treatment of diabetes are also described.

  化合物的化学式（I）或其药用可接受的盐，其中化学式（I）中Ar是可选择的取代苯基；R1选自：化学式a）或b）（其中是单键或双键）；R5、R6、R7和R8例如是氢或烷基；R4选自氢、（3-4C）环烷基和可选择的取代（1-4C）烷基；R10例如选自氢、（1-4C）烷基、（3-6C）环烷基（1-4C）烷基、羟基（1-4C）烷基、（1-4C）烷氧基、芳基（1-4C）烷基；Y是碳，环A是可选择的取代苯基；或每个Y可以独立地是碳或氮，环A是可选择的取代的5-或6-成员的杂芳烃环；R11选自氢和可选择的取代苯基；p在每次出现时独立地为0、1或2；描述了制备这类化合物的过程以及它们作为DPP-IV抑制剂在糖尿病治疗中的用途。